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8 Oral Presentationscumulative incidence of transplant related-mortality and relapse
was 9.96 4%, 24.86 5%, respectively. Inmultivariate analyses, ad-
vanced disease status was an adverse factor for DFS (p5 0.001) and
relapse (p5 0.007). These results suggest that adult acute leukemia
patients without suitable related or unrelated bone marrow donors
should be considered as candidates for CBT.
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THE IMPACT OF RESOLVED HEPATITIS B INFECTION ON ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL MALIGNANCIES
Ramos, C.A., Saliba, R.M., Giralt, S., Khorshid, O., de Padua, L.,
Andersson, B.S., Nieto, Y.L., Popat, U.R., Qazilbash, M.H.,
Qureshi, S., Zhang, W., Champlin, R.E., de Lima, M. The University
of Texas MD Anderson Cancer Center, Houston, TX.
Serological evidence of resolved hepatitis B (HB) infection has
been associated with reactivation of hepatitis after allogeneic SCT
(alloSCT), but the true impact of this finding is unknown. We hy-
pothesized that reactivation of HB could lead to worse outcomes in
patients following alloSCT.
We conducted a retrospective matched-control analysis of the
outcomes of 77 patients with positive HB core antibody (HBcAb)
and negative HB surface antigen (HBsAg) at the time of alloSCT.
All patients had hematological malignancies (including AML,
CML, lymphoma, ALL, CLL and myeloma) and were transplanted
between 1998 and 2007. Control patients (with negative serology
for HB and other viral hepatitides) were matched by age, diagnosis,
disease risk (poor vs. good), intensity of conditioning regimen (re-
duced vs. myeloablative) and donor type. Poor risk was defined as
not being in remission or not having chemosensitive tumor before
transplant, depending on the specific disease. When possible, if
multiple matches were available, a control patient with the same ex-
act disease stage, conditioning regimen and graft source (blood or
bone marrow) was selected. Three patients were dropped from
the comparison because no appropriate matched control was avail-
able.
The control and study groups had similar baseline patient charac-
teristics regarding age (median 50 and 49, respectively), poor risk
(51% in both groups), sibling donor (73%), reduced intensity con-
ditioning (42%) and diagnosis. Follow-up serological studies done
after transplant documented reactivation of hepatitis B (defined as
the emergence of positive HBsAg) in 8 (10%) of the initially HBcAb
positive and HBsAg negative patients. Two of these patients re-
verted back to HBsAg negativity after a period of moderate eleva-
tion of liver enzymes and are long term survivors. The other 6
patients had persistent mild elevation of ALT and AST: 2 became
long term survivors, 2 died of chronic GVHD (with liver involve-
ment) and 2 died from progression of disease. Loss of antibody re-
sponse to HBc antigen with persistent negativity of HBsAg was
documented in 23 patients (30%). There were no significant differ-
ences in overall survival, relapse and non-relapse mortality and in-
cidence of acute GVHD between HBcAb positive and control
groups. In conclusion, positive HBcAb status at the time of trans-
plant does not seem to adversely affect outcomes, despite being as-
sociated with reactivation ofHB infection in at least 10% of patients
after alloSCT.
Overall survival and non-relapse mortality are comparable in HepBcAb
positive patients and matched controls after SCT
Outcome HepBcAb, % Control, % HR (95% CI) POS:
1 yr 66 64 0.99 (0.6–1.7) 0.9
2 yr 51 55 1.1 (0.7–1.8) 0.7NRM:
3 mo 11 5 2.1 (0.6–6.9) 0.2
1 yr 25 17 1.5 (0.7–3.1) 0.3
2 yr 31 21 1.5 (0.7–3.1) 0.3OS: overall survival; NRM: non-relapse mortality; HR: hazard
ratio; CI: confidence interval.16
LONG-TERM RESULTS OF A GITMO RETROSPECTIVE STUDY ON HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA (PNH)
Santarone, S.1, Di Bartolomeo, E.1, Bacigalupo, A.2, Tagliaferri, E.3,
Iori, A.4, Risitano, A.5, Tamiazzo, S.6, Papineschi, F.7, Rambaldi, A.8,
Spagnoli, A.9, Angelucci, E.10, Di Bartolomeo, P.1. 1BMT Center, Pes-
cara, Italy; 2BMT Center, Genova, Italy; 3BMT Center, Milano, Italy;
4BMTCenter, University La Sapienza, Roma, Italy; 5BMTCenter, Na-
poli, Italy; 6BMT Center, Alessandria, Italy; 7BMT Center, Pisa, Italy;
8BMT Center, Bergamo, Italy; 9BMT Center, S.Eugenio Hospital,
Roma, Italy; 10BMT Center, Cagliari, Italy.
Allogeneic HSCTmay cure PNH. In this study we report the re-
sults of allogeneic HSCT in 26 patients (16 males and 10 females)
affected by PNH who were transplanted between July 1988 and
May 2007. The median age at time of HSCT was 32 years (20–
60). The median time from diagnosis to HSCT was 33 months
(3–208). All patients had received various treatments before
HSCT including steroids, immunosuppressive drugs and growth
factors. Twenty-one patients were transfusion-dependent. The me-
dian number of packed red blood cells and platelet concentrates re-
ceived before HSCT was 30 (4–500) and 22 (6–86) respectively. At
time of HSCT, the median peripheral hematological counts were:
polymorphonucleates (PMN) 2200 (20–10204)  109/L, hemoglo-
bin 8.7 g/dl (4.6–11), platelets (PLT) 78 (6–355)  109/L. Two pa-
tients were severely pancytopenic at time of HSCT. Twenty-four
patients were transplanted from HLA identical siblings and 2
from matched unrelated donors. The donor’s median age was 33
years (20–59). The conditioning regimen was myeloablative for
16 patients (Busulfan and Cyclophosphamide), whereas 10 patients
received a reduced intensity conditioning including Fludarabine,
Cyclophosphamide, Melphalan and Total Body Irradiation. As
graft-versus-host disease (GvHD) prophylaxis, 11 patients received
Cyclosporine (CSA) alone and 13 were given CSA and short course
Methotrexate. Two patients received T-cell depleted marrow cells.
Twenty patients were given bone marrow cells (median nucleated
cells 4.1 (2.5–7.5)  108/kg) and 6 received peripheral blood stem
cells (median CD341 cells 4.6 (2.8–7.1)  106/Kg). Twenty-five
patients achieved primary sustained engraftment with a median
time of 17 (10–38) days to reach .0.5  109/L PMN and 27 (11–
322) days to reach .50  109/L PLT. The probability of develop-
ing grade II-IV acute GvHDand extensive chronicGvHDwas 42%
and 16% respectively. The transplant related mortality at 6 months
was 34%. Causes of death were infection in 4 patients, acute GvHD
in 1, chronicGvHD in 2, multi-organ failure in 1 and EBV lympho-
proliferative disease in 1. As of October 2007, 16 patients are alive
with complete hematological recovery and no evidence of PNH at
a median follow-up of 107 months (6–210). The 10-year Kaplan-
Meier probability of disease-free survival is 62%. No patient devel-
oped thromboembolic disease following HSCT. This study con-
firms that HSCT is a curative treatment for the majority of
patients with PNH.17
PRE-TRANSPLANT INFUSION OF NATURALLY OCCURRING DONOR
CD41 CD251 T CELLS SUPPORTS DONOR CHIMERISM IN MHC-
MATCHED ALLOGENEIC HCT
Shatry, A.M., Levy, R.B. University of MiamiMiller School of Medicine,
Miami, FL.
Resistance to MHC matched allogeneic hematopoietic stem cell
transplant (HCT) is mediated by host T cells and remains a major
complication to successful donor HCT engraftment under reduced
intensity conditioning. We examined the ability of unmanipulated
donor CD41 CD251 regulatory T cells (Tregs) to support donor
HCT engraftment to test the hypothesis that Treg suppression of
host effector CD81 T anti-donor responses would enhance donor
HCT engraftment. Mice disparate for multiple minor HA were uti-
lized for these studies: C57BL/6 (H-2b, Ly9.1-) mice conditioned
(5.5 Gy TBI) 24 hrs earlier, were transplanted with Tregs and
TCD-BM from 129P3/J (H-2b, Ly9.11) mice. By four weeks
post-HCT, the mean frequency of circulating donor-derived (total
Ly9.11) cells was significantly higher in recipients of 4  106
